Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Non-Current Liabilities: 2019-2023

Historic Total Non-Current Liabilities for Silence Therapeutics (SLN) over the last 5 years, with Dec 2023 value amounting to $73.2 million.

  • Silence Therapeutics' Total Non-Current Liabilities rose 0.80% to -$75.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$75.3 million, marking a year-over-year increase of 0.80%. This contributed to the annual value of $73.2 million for FY2023, which is 6.79% down from last year.
  • Silence Therapeutics' Total Non-Current Liabilities amounted to $73.2 million in FY2023, which was down 6.79% from $78.6 million recorded in FY2022.
  • Over the past 5 years, Silence Therapeutics' Total Non-Current Liabilities peaked at $99.8 million during FY2021, and registered a low of $19.8 million during FY2019.
  • For the 3-year period, Silence Therapeutics' Total Non-Current Liabilities averaged around $83.9 million, with its median value being $78.6 million (2022).
  • Per our database at Business Quant, Silence Therapeutics' Total Non-Current Liabilities soared by 232.78% in 2020 and then declined by 21.24% in 2022.
  • Silence Therapeutics' Total Non-Current Liabilities (Yearly) stood at $19.8 million in 2019, then surged by 232.78% to $65.9 million in 2020, then soared by 51.31% to $99.8 million in 2021, then dropped by 21.24% to $78.6 million in 2022, then decreased by 6.79% to $73.2 million in 2023.